CD19 and cancer: Using CAR T and CAR NK cells generated under identical manufacturing processes with a benchmark CAR construct [24] used in an approved CAR T cell product (axi-cel), we demonstrated that CD19 directed human CAR T and CAR NK cells displayed similar cytotoxicity against established CD19+ cancer cell lines in vitro in models of both acute and chronic stimulation.